Douglas Melamed

Doug Melamed is Professor of the Practice of Law at Stanford Law School.  He joined the Stanford faculty in 2014.  In the Fall of 2017, he was the Florence Rogatz Visiting Professor in the Practice of Law at Yale Law School.

From 2009 until 2014, Doug was Senior Vice President and General Counsel of Intel Corporation and was responsible for overseeing Intel’s legal, government affairs, and corporate affairs departments. Prior to joining Intel in 2009, he was a partner in the Washington, D.C., office of WilmerHale, a global law firm in which he served as a chair of the Antitrust and Competition Practice Group.  From 1996 to 2001, he served in the U.S. Department of Justice as Acting Assistant Attorney General in charge of the Antitrust Division and, before that, as Principal Deputy Assistant Attorney General.

Doug has authored numerous articles on antitrust, patent law, and law and economics. He is a member of the American Law Institute and a Contributing Editor of the Antitrust Law Journal and a former member of the boards of directors of the Nasdaq exchanges.  Doug received his B.A. from Yale and his J.D. from Harvard, where he was an editor of the Harvard Law Review.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More